Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A Two-Pronged immune attack against HPV: could it prevent cervical cancer?

NCT ID NCT07735039

Disease control Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial tests whether combining an oral immunomodulator with a vaginal ovule can help the body clear persistent high-risk human papillomavirus (HPV) infection, a key cause of cervical cancer. About 76 women with low-grade cervical changes will receive either the dual immunotherapy or standard supportive care for three months. The main goal is to see if the treatment leads to a negative HPV test afterward.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an oral immunomodulator plus a vaginal ovule
What this could lead to
If effective, this dual immunotherapy could offer a non-surgical way to clear high-risk HPV and reduce the risk of cervical cancer.
What could go wrong
This is a small, early-stage trial with only 76 participants, so results may not apply broadly. The treatment may cause side effects or fail to improve HPV clearance over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

76 people

The number who actually took part.

Started

Apr 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18-65 years. * Confirmed persistent high-risk human papillomavirus (HR-HPV) infection. * Histologically confirmed CIN 1 or cytological diagnosis of ASC-US or LSIL. * Eligible for conservative follow-up without immediate excisional treatment. * Ability to provide written informed consent and comply with study procedures. Exclusion Criteria: * HSIL, CIN2, CIN3, adenocarcinoma in situ, or invasive cervical cancer. * Pregnancy or breastfeeding. * Immunodeficiency or current immunosuppressive therapy. * Previous treatment for cervical dysplasia within the last 6 months. * Planned colposcopy, cervical biopsy, or LEEP during the 3-month study period. * Known hypersensitivity to any study intervention. * Participation in another interventional clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical intraepithelial neoplasia (CIN) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Atypical Squamous Cells of the Cervix cervical intraepithelial neoplasia dysplasia of cervix human papilloma virus infection squamous cell intraepithelial neoplasia Squamous Intraepithelial Lesions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical intraepithelial neoplasia (CIN) Human papillomavirus infection Low-grade squamous intraepithelial lesions

Contacts and locations

Locations

  • University of Health Sciences Turkey, Kartal Dr. Lütfi Kırdar City Hospital

    Istanbul, Istanbul, 34865, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.